| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,007,149 | 3 | 100 |
| Zummo Jacqueline | Chief R&D Officer | 0 | $0 | 2 | $124,989 | $-124,989 |
| Shefferman Jesse | CEO and President | 0 | $0 | 1 | $882,160 | $-882,160 |
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate …
Over the last 12 months, insiders at Protara Therapeutics, Inc. have bought $0 and sold $1.01M worth of Protara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protara Therapeutics, Inc. have bought $496,535 and sold $723,858 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $63,800 was made by Levy Richard S (director) on 2025‑05‑14.
| 2026-06-29 | Sale | Shefferman Jesse | CEO and President | 215,687 0.5495% | $4.09 | $882,160 | -6.97% | |
| 2026-04-08 | Sale | Zummo Jacqueline | Chief R&D Officer | 1,134 0.0031% | $5.40 | $6,124 | -23.37% | |
| 2026-04-01 | Sale | Zummo Jacqueline | Chief R&D Officer | 22,598 0.0611% | $5.26 | $118,865 | -20.63% | |
| 2025-05-14 | Levy Richard S | director | 20,000 0.0528% | $3.19 | $63,800 | +63.90% | ||
| 2025-03-26 | Sale | Zummo Jacqueline | Chf Scientific Operations Off | 21,224 0.0577% | $4.53 | $96,145 | -5.30% | |
| 2024-09-12 | Sale | Opaleye Management Inc. | 10 percent owner | 126,301 0.6048% | $1.71 | $215,836 | +87.57% | |
| 2024-09-11 | Sale | Opaleye Management Inc. | 10 percent owner | 32,600 0.1566% | $1.71 | $55,880 | +90.88% | |
| 2024-09-10 | Sale | Opaleye Management Inc. | 10 percent owner | 25,500 0.1264% | $1.77 | $45,110 | +87.57% | |
| 2024-09-09 | Sale | Opaleye Management Inc. | 10 percent owner | 36,492 0.1821% | $1.89 | $69,141 | +76.36% | |
| 2024-07-16 | Sale | Opaleye Management Inc. | 10 percent owner | 11,396 0.0691% | $2.44 | $27,828 | +31.67% | |
| 2024-07-11 | Sale | Opaleye Management Inc. | 10 percent owner | 47,993 0.2866% | $2.40 | $115,346 | +34.83% | |
| 2024-07-10 | Sale | Opaleye Management Inc. | 10 percent owner | 18,061 0.1036% | $2.31 | $41,685 | +36.58% | |
| 2024-07-09 | Sale | Opaleye Management Inc. | 10 percent owner | 8,497 0.0467% | $2.21 | $18,811 | +48.12% | |
| 2024-07-01 | Sale | Opaleye Management Inc. | 10 percent owner | 8,288 0.0437% | $2.12 | $17,598 | +50.48% | |
| 2024-06-28 | Sale | Opaleye Management Inc. | 10 percent owner | 17,994 0.0927% | $2.07 | $37,334 | +51.44% | |
| 2024-06-27 | Sale | Opaleye Management Inc. | 10 percent owner | 46,574 0.2613% | $2.26 | $105,169 | +44.93% | |
| 2024-06-25 | Sale | Opaleye Management Inc. | 10 percent owner | 12,725 0.0665% | $2.26 | $28,734 | +49.76% | |
| 2024-05-31 | Sale | Opaleye Management Inc. | 10 percent owner | 5,824 0.0292% | $2.90 | $16,895 | +2.85% | |
| 2024-05-30 | Sale | Opaleye Management Inc. | 10 percent owner | 9,230 0.0454% | $2.94 | $27,113 | -1.55% | |
| 2024-05-22 | Sale | Opaleye Management Inc. | 10 percent owner | 9,800 0.0481% | $3.02 | $29,596 | -6.35% |
| Shefferman Jesse | CEO and President | 721832 1.2215% | $1.74M | 1 | 1 | <0.0001% |
| O'Leary Brendan | director | 1387198 2.3474% | $3.34M | 1 | 0 | |
| Abingworth LLP | 10 percent owner | 950000 1.6076% | $2.29M | 1 | 0 | |
| Haines Timothy | 950000 1.6076% | $2.29M | 1 | 0 | ||
| Pharmstandard International S.A. | 10 percent owner | 600000 1.0153% | $1.45M | 1 | 0 | |
| Kobyzev Dmitry | 600000 1.0153% | $1.45M | 1 | 0 | ||
| Birner Hubert | 300000 0.5077% | $723,000.00 | 1 | 0 | ||
| TVM Life Science Ventures VI GmbH & Co KG | 10 percent owner | 300000 0.5077% | $723,000.00 | 1 | 0 | |
| Freund John Gordon | 200000 0.3384% | $482,000.00 | 1 | 1 | ||
| Skyline Venture Partners Qualified Purchaser Fund IV L P | 10 percent owner | 200000 0.3384% | $482,000.00 | 1 | 1 | |
| BESHAR LUKE M | 198000 0.3351% | $477,180.00 | 3 | 0 | <0.0001% | |
| Flynn James E | director | 197424 0.3341% | $475,791.84 | 2 | 1 | |
| Burke Steven Keith | SVP and Chief Medical Officer | 117535 0.1989% | $283,259.35 | 1 | 0 | |
| Levy Richard S | director | 51000 0.0863% | $122,910.00 | 1 | 0 | +63.9% |
| Opaleye Management Inc. | 10 percent owner | 45000 0.0761% | $108,450.00 | 15 | 20 | <0.0001% |
| Olivo Martin Sebastian | Chief Medical Officer | 14344 0.0243% | $34,569.04 | 1 | 0 | <0.0001% |
| Eldridge, George Arthur | Sr VP, CFO, Treasr, Asst Secy | 1545 0.0026% | $3,723.45 | 2 | 0 | |
| Davis Blaine | Chief Financial Officer | 1481 0.0025% | $3,569.21 | 1 | 0 | <0.0001% |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 76 | +124.59% | 15M | +55.72% |
| Decreased Positions | 24 | -39.34% | 1M | -3.88% |
| New Positions | 31 | New | 6M | New |
| Sold Out Positions | 8 | Sold Out | 539,694 | Sold Out |
| Total Postitions | 113 | +85.25% | 40M | +51.83% |
| Janus Henderson Group Plc | $22,765.00 | 8.14% | 4.23M | +128,711 | +3.14% | 2025-09-30 |
| Blackrock, Inc. | $11,994.00 | 4.29% | 2.23M | +85,488 | +3.99% | 2025-09-30 |
| Velan Capital Investment Management Lp | $11,508.00 | 4.11% | 2.14M | 0 | 0% | 2025-09-30 |
| Blackstone Inc. | $10,274.00 | 3.67% | 1.91M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $10,244.00 | 3.66% | 1.9M | +102,176 | +5.67% | 2025-09-30 |
| Acorn Capital Advisors, Llc | $9,426.00 | 3.37% | 1.75M | 0 | 0% | 2025-09-30 |
| Catalio Capital Management, Lp | $8,074.00 | 2.89% | 1.5M | -125,577 | -7.72% | 2025-09-30 |
| Integral Health Asset Management, Llc | $7,532.00 | 2.69% | 1.4M | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $4,536.00 | 1.62% | 843,074 | -292,693 | -25.77% | 2025-09-30 |
| 5Am Venture Management, Llc | $4,304.00 | 1.54% | 800,000 | 0 | 0% | 2025-09-30 |